Skip to main content
. Author manuscript; available in PMC: 2020 Oct 30.
Published in final edited form as: Leukemia. 2020 Jan 27;34(7):1816–1827. doi: 10.1038/s41375-020-0710-7

Figure 4.

Figure 4.

Decrease of p53 target gene GADD45A also contributes to drug resistance.

(A) Gene expression and protein level were tested in chemoresistant and their parental cells. (B) Correlation of GADD45A gene transcript z-scores and Ara-C compound activities (-log values) z-scores in NCI60 cells. (C) MV4–11, MV4–11 R4 and MV4–11 single cell clone with TP53mut were treated with either vehicle or 1µM Ara-C for 24h. #P<0.05 compared with MV4–11 group. $P<0.05 compared with MV4–11 treated with Ara-C group. (D) shRNA knocking down efficiency of GADD45A in OCI-AML2 cells was tested (left). MTS assay was performed to test drug response in control and knockdown cells after 72h drug treatment (right). Bars indicate the standard error of mean. *P < 0.05